title: Acute pericarditis and pleural effusion complicating cytarabine chemotherapy.
abstract: BACKGROUND
  Pericarditis is a rare but possibly severe complication of treatment of acute leukemia with cytarabine.
  
  
  METHODS
  We report a possibly cytarabine-induced acute pericarditis and pleuritis with a rapid onset. A patient with acute myelomonocytic leukemia developed an isolated pericarditis 3 weeks after the first course of chemotherapy with cytarabine and idarubicin. The second course of chemotherapy with cytarabine and amsacrine was started after clinical improvement; 3 days later an acute pericarditis with a large pericardial effusion accompanied by a left pleural effusion developed. A pericardio- and pleuracentesis was performed and the symptoms improved rapidly without reaccumulation of the fluid. The third course of chemotherapy with mitoxantrone and etoposide was completed without further cardiopulmonary complications.
  
  
  CONCLUSIONS
  The differential diagnosis of pericarditis in the setting of chemotherapy with cytarabine should include cytarabine- induced pericarditis. The pathogenesis remains unclear, directly toxic and immunological mechanisms are suggested. Severe progression with massive pericardial effusion necessitating risky pericardiocentesis can occur and therefore a therapy with high-dose corticosteroids should be considered early.
authors.affiliation: Abteilung Onkologie und Hämatologie, Kantonsspital St. Gallen, Switzerland. anita.gaehler@kssg.ch
authors.forename: A
authors.initials: A
authors.lastname: Gähler
authors.forename: F
authors.initials: F
authors.lastname: Hitz
authors.forename: U
authors.initials: U
authors.lastname: Hess
authors.forename: T
authors.initials: T
authors.lastname: Cerny
mesh_terms: D000208:Acute Disease; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010493:Pericarditis / Q000139:chemically induced* / Q000175:diagnosis; D010996:Pleural Effusion / Q000139:chemically induced* / Q000175:diagnosis; D012008:Recurrence
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine